Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 7/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8663839 | 0.89 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KAT2BBAZ2B | |
| SCHEMBL3799931 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BPDE4APDE4DPDE4B | |
| SCHEMBL1928288 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BPDE4APDE4DPDE4B | |
| SCHEMBL29186583 | 0.79 | KAT2B (0.47) | KAT2BBAZ2BPDE4APDE4DPDE4B | |
| SCHEMBL1927820 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BPDE4APDE4DPDE4B | |
| SCHEMBL7760101 | 0.79 | KAT2B (0.47) | SLC6A4SLC6A2SLC6A3KAT2BBAZ2B | |
| SCHEMBL3801070 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BPDE4APDE4DPDE4B | |
| SCHEMBL1928290 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BPDE4APDE4DPDE4B | |
| SCHEMBL3795839 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BPDE4APDE4DPDE4B | |
| SCHEMBL9281104 | 0.79 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | SLC6A4 3465/4885SLC6A2 3036/4885SLC6A3 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.